The Triple-Agonist Race: Retatrutide, Twenty-Seven Programs, and the Hidden Patent War Behind the Next Obesity Market.
Published Date: 04.28.2026
Ozempic and Wegovy built a $50B market with 15% weight loss. Mounjaro and Zepbound redefined it at 22%. In April 2026, retatrutide crossed 28.7% — matching bariatric surgery. Twenty-seven triple agonists are now racing behind it. Sanofi holds the largest latent IP position in the field and has no disclosed program. This report maps who owns what, who is building what, and what the Last 20% of trial-to-real-world compression will mean for the winners.
MDB Capital is a wholly-owned subsidiary of MDB Capital Holdings (Nasdaq: MDBH) and a broker-dealer registered with the U.S. Securities and Exchange Commission, a member of FINRA and a member of SIPC. Securities trading, account management, and investment banking services are offered by MDB Capital.
PatentVest, Inc. is a wholly owned subsidiary of MDB Capital Holdings and an affiliated company of MDB Capital.
